Even for companies with massive R&D output, targeted deals with SEP-focused research labs seem to fit a strategic need
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Author | Editor
@IAM_Alerts RT @IAM_Alerts: This week’s Sunday Supplement is now out, including: Auto IP conflict heats up; Honor nets BlackBerry patents; Unprecedente… Read more
@IAM_Alerts This week’s Sunday Supplement is now out, including: Auto IP conflict heats up; Honor nets BlackBerry patents; Unpr… https://t.co/oEf2zzUtIq Read more
@IAM_Alerts The IAM Saturday Opinion: takeaways from an eventful two weeks in auto IP https://t.co/7xphmhyc6S https://t.co/I8L7xIvh7K Read more
@IAM_Alerts Despite being a short-term PR success, Moderna’s covid-19 patent pledge may be backfiring: https://t.co/Xuq74jEoCq https://t.co/oHbxS4kjuL Read more